Foley Hoag Advises Abiomed as Lead Investor in $15M Series B Financing of Magenta Medical

October 12, 2017

Foley Hoag LLP recently represented Abiomed, Inc. (NASDAQ: ABMD) in its investment in medical device company Magenta Medical. Based in Danvers, MA, Abiomed is a leading provider of medical devices that provide circulatory support. Abiomed led the $15 million Series B financing round, with participation from Pitango Venture Capital, JAFCO Co., Ltd., and a group of industry and cardiovascular experts.

With headquarters in Tel-Aviv, Israel, Magenta develops devices for the treatment of acute heart failure. Magenta will use the funds to position itself as a groundbreaker in the management and treatment of acute heart failure, and to expand and accelerate clinical trials in Europe and the United States.

Foley Hoag partner Mark Haddad represented Abiomed in the transaction.

About Foley Hoag LLP

Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse backgrounds, perspectives and experiences of our lawyers and staff contribute to the exceptional senior level service we deliver to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.